Search

Your search keyword '"Baker LH"' showing total 295 results

Search Constraints

Start Over You searched for: Author "Baker LH" Remove constraint Author: "Baker LH"
295 results on '"Baker LH"'

Search Results

51. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.

52. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

54. Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.

55. Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.

56. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).

57. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities.

58. Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701).

59. Moving a randomized clinical trial into an observational cohort.

60. Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma.

61. Generic sirolimus: a future opportunity to decrease the cost of oncology care?

62. When progressive disease does not mean treatment failure: reconsidering the criteria for progression.

63. Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process.

64. Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma.

66. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.

67. Cancer survivors in the United States: a review of the literature and a call to action.

68. How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment.

69. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.

70. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

71. SWOG Cooperative Group biorepository resource: access for scientific research studies.

72. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.

73. Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.

74. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.

75. Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations.

76. The development and testing of a measure assessing clinician beliefs about patient self-management.

77. Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008.

78. Pharmacotherapy of sarcoma.

79. Small round cell sarcomas.

80. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

81. Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.

82. Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation.

83. Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors.

84. New agents for sarcoma.

85. Chordoma: the nonsarcoma primary bone tumor.

86. Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma.

87. Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.

88. Soft tissue sarcoma.

89. Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines.

90. Pulmonary nodule volumetric measurement variability as a function of CT slice thickness and nodule morphology.

91. Gardner's syndrome in a 40-year-old woman: successful treatment of locally aggressive desmoid tumors with cytotoxic chemotherapy.

92. Primary versus radiation-associated craniofacial osteosarcoma: Biologic and clinicopathologic comparisons.

93. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme.

94. Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition.

97. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy.

99. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma.

100. Bone cancer clinical practice guidelines.

Catalog

Books, media, physical & digital resources